Author

Lynn Su

The University of Texas Health Science Center at Houston

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adela M. Aldana· 1 shared Bin Tang YangiD· 1 shared Jake Jianjun WeniD· 1 shared Jianghua TuiD· 1 shared Jie Cui· 1 shared Jin WangiD· 1 shared Li LiiD· 1 shared Ling WuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Adela M. Aldana

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

RSPO2-based peptibodies conjugated with pyrrolobenzodiazepine dimer or camptothecin analogs demonstrate potent anti-tumor activity by targeting the three receptors LGR4/5/6 in colorectal cancer and neuroblastoma

Yukimatsu Toh, Jianghua Tu, Ling Wu, Adela M. Aldana, Jake Jianjun Wen, Lynn Su, Bin Tang Yang, Xiaowen Liang, Li Li, Sheng Pan, Jin Wang, Jie Cui, Qingyun J. Liu

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

Journal of Medicinal Chemistry · Apr 9, 2026Peer-reviewedPharmacology & Toxicology